ClinicalTrials.gg
TerminatedNCT00779285Updated Jul 14, 2015Results posted

Safety Study of CAELYX in Patients With Metastatic Breast Cancer Previously Treated With Anthracyclines (Study P04057)(TERMINATED)

A Phase 4 interventional study of Pegylated Liposomal Doxorubicin in Breast Neoplasm, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-07-14.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1
Allocation
Not applicable
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.

Enrollment
64th of 66
1 · median 57
Started
2006
with 7 others
Phase 4
6 of 67
none open now
Registered
32nd of 67
by date
Lead sponsor
5 of 67
Merck Sharp & Dohme LLC

Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one is the 64th largest by enrollment of the 66 interventional ones that give a count, is one of 8 that started in 2006, is one of 6 in phase 4, and was the 32nd registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About liposomal doxorubicin

liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 67 studies testing liposomal doxorubicin in Breast Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the cardiac safety of Caelyx in patients with metastatic breast cancer who have previously received chemotherapy with anthracyclines.

03

Conditions studied

  • Breast Neoplasm

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women with or cytologically confirmed breast cancer (no prior chemotherapy for metastatic disease).
  • Prior treatment with an anthracyclin-containing regimen in the setting (cumulative dose >240mg/m\^2 and \<360mg/m\^2 doxorubicin or >430mg/m\^2 and \<650mg/m\^2 epirubicin).
  • Women >18 years of age.
  • Documented measurable and/or evaluable metastatic breast cancer by appropriate radiological imaging (computed tomography (CT) scan and/or magnetic resonance imaging (MRI)).
  • Performance status of at least 60% ( index) and a of at least 12 weeks.
  • >50%.
  • Normal organ function, except if abnormal due to tumor involvement.

    • Adequate bone marrow function as indicated:

      • >100,000/mm\^3
      • >9 g/dL
      • Neutrophils >1,500/mm\^3
    • Adequate renal function as indicated by:

      • Serum Creatinine \<1.5 x the
    • Adequate liver function, as indicated by:

      • and (AST) or alanine aminotransferase (ALT) \<2 times upper limit of normal (\<4 times upper limit of normal when related to primary disease)
  • Subjects must be capable to demonstrate their willingness to participate in the study and comply with its procedures by signing a written .
  • Women of (includes women who are less than 1 year and women who become sexually active) must be using an acceptable method of (e.g., hormonal contraceptive, medically prescribed intrauterine device (IUD), condom in combination with spermicide) or be surgically sterilized (e.g., hysterectomy or tubal ligation).
  • Subjects must understand and be able to adhere to the dosing and visit schedules.

Exclusion criteria

Exclusion Criteria:

  • Patient is pregnant or is breastfeeding.
  • Patients with moderate or severe heart failure ( (NYHA) class III/IV).
  • to anthracycline therapy or a history of severe hypersensitivity reactions to products containing Cremophor® EL (e.g., cyclosporin for injection concentrate and teniposide for injection concentrate).
  • Prior chemotherapy for disease.
  • hepatic disease (except liver metastases of primary disease).
  • Uncontrolled bacterial, viral, or fungal infection.
  • Radiotherapy in the last 4 weeks or prior radiation therapy to more than one-third of the hemopoietic sites.
  • Any other currently known or pre-malignant lesions or any history of other malignancy within the past five years (except non-melanoma skin cancer and surgically cured cervical cancer).
  • Symptomatic .
  • Patients who are incapacitated, largely or wholly bedridden or confined to a wheelchair, and who have little or no ability for self-care.
  • Current signs or symptoms of severe, progressive or uncontrolled renal, hepatic, hematologic, endocrine, pulmonary, cardiac, neurological or cerebral disease.
  • Documented (HIV) infection.
  • Any condition (medical, social, psychological) which would prevent adequate follow-up.
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1 participant (actual)

Study arms

  • Experimental
    Single-arm

    Pegylated Lyposomal Doxorubicin (Caelyx) 50 mg/m2, given for 6 cycles

    Drug: Pegylated Liposomal Doxorubicin

Interventions

  • Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.

    Also known as: SCH 200746

06

What researchers measure

Primary outcomes

  1. Cardiac Events

    A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of \>=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of \>=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).

    Time frame: Every 4 weeks during 6 cycles.

07

Results

Posted Mar 10, 2010

Participant flow

Participant flow — Overall Study
MilestoneCaelyx
Started1
Completed1
Not completed0

Outcome measures

PrimaryCardiac Events

A cardiac event was defined as a decrease in left ventricular ejection fraction (LVEF) of \>=20 points from baseline if the resting LVEF remained in the normal range, or a decrease of \>=10 points if the LVEF became abnormal (lower than the institutional lower limit of normal).

Time frame:
Every 4 weeks during 6 cycles.
Reported as:
Number · Cardiac Events
Cardiac Events
Cardiac EventsCaelyx
Cardiac Events0

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Caelyx—0/1 (0%)1/1 (100%)
Most frequent other events
Most frequent other events
EventCaelyx
Maculopapulosus exanthemaSkin and subcutaneous tissue disorders1/1

Baseline characteristics

Age, Customized
Age, Customized(participants)Caelyx
Number1
Sex: Female, Male
Sex: Female, Male(Participants)Caelyx
Female1
Male0
Region of Enrollment
Region of Enrollment(participants)Caelyx
Hungary1
08

Study locations

No study locations are listed for this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2006, a primary completion of Aug 2006 and a completion of Aug 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2010, 3 years 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 23, 2008
First posted
Oct 24, 2008
Start
Feb 2006
Primary completionActual
Aug 2006
CompletionActual
Aug 2006
Results first posted
Mar 10, 2010
Last update
Jul 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00779285
Responsible party
Sponsor
First posted
Oct 24, 2008
Start date
Feb 2006
Primary completion
Aug 2006
Completion
Aug 2006
Results posted
Mar 10, 2010
Last update
Jul 14, 2015

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Liposomal doxorubicin

Start the discussion